Cipla Limited has informed its shareholders and creditors of an order passed by the National Company Law Tribunal (NCLT), Mumbai Bench, on August 18, 2026. The tribunal approved directions for the scheme of amalgamation by absorption of Inzpera Healthsciences Limited into Cipla.

The company issued notices under Section 230(5) of the Companies Act, 2013, to all equity shareholders and unsecured creditors. These notices were dispatched via electronic mode where email addresses were available and through physical mail for others.

Stakeholder Response Window

Stakeholders may submit representations regarding the proposed scheme to the NCLT within 30 days from the date of receipt of the notice. A copy of any representation must also be sent to Cipla’s registered office in Mumbai.

If no response is received within this period, the tribunal will presume that the concerned shareholder or creditor has no objection to the scheme.

Regulatory Context

The NCLT order, dated August 18, 2026, dispensed with the requirement for meetings of equity shareholders and unsecured creditors of the transferee company. As there are no secured creditors involved in the transaction, no meeting of secured creditors was required.

This disclosure is made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The relevant documents, including the notice, NCLT order, and scheme details, are available on the company’s website.

Cipla has entered into an exclusive licensing agreement with SBP Group for the HER2 bispecific antibody-drug conjugate (ADC) rolditamig deuderuxtecan (TQB2102), covering India, South Africa, and five other emerging markets. The deal, announced on August 31, 2026, aims to accelerate patient access to this potential best-in-class oncology therapy.

Deal structure and market scope

Under the agreement, Cipla will be responsible for local clinical development, regulatory activities, and commercial sales of rolditamig deuderuxtecan across the licensed territories. The deal spans a total of seven markets, with India and South Africa explicitly named alongside five additional emerging markets. SBP Group’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), will continue to manufacture and supply TQB2102.

Key deal parameters

The following table summarises the known parameters of the licensing agreement:

Rolditamig deuderuxtecan, designated TQB2102, is a next-generation HER2 dual-epitope bispecific ADC independently developed by SBP Group. It simultaneously binds to the ECD II and ECD IV domains of HER2 and incorporates a cleavable linker and topoisomerase I inhibitor payload. This differentiated design is intended to overcome limitations associated with conventional HER2 monoclonal antibodies or single-target ADCs, potentially enhancing receptor cross-linking and endocytosis efficiency in patients with HER2-low expression.

Clinical potential and regulatory status

TQB2102 has received three Breakthrough Therapy Designations from the Center for Drug Evaluation of China's National Medical Products Administration. It is currently being evaluated for HER2-low, HER2-positive breast cancer, colorectal cancer, and biliary tract cancer across multiple treatment settings. The asset has demonstrated encouraging clinical potential in HER2-low advanced breast cancer.

Strategic rationale

Achin Gupta, Managing Director and Global Chief Executive Officer of Cipla, stated that the agreement strengthens the company’s oncology portfolio with a promising HER2-targeted antibody-drug conjugate. He noted that breast cancer remains a significant healthcare challenge and that the partnership aims to accelerate development and expand access subject to regulatory approvals.

Eric Tse, CEO of SBP Group, highlighted that expanding global access to medicines is central to their strategy. He cited Cipla’s scale, local expertise, and commitment to patient access as key factors in selecting it as a partner for India, South Africa, and other emerging markets.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE059A01026/b5ca36cd-3407-4f2f-9182-8b004f794ce4.pdf